HYBRID MODELS FOR HEART FAILURE MEDICATION OPTMIZATION- LOOKING AHEADBASED ON LEARNINGS FROM THE COVID-19 PANDEMIC (CCC-204)

Workshop Description:

Planning committee:
Rody Pike- Nurse Practitioner, Newfoundland (Co-Chair)
Kim Anderson- Cardiologist, Nova Scotia
Lynette Kosar- Pharmacist, Saskatchewan
Wynne Chiu- Clinical Nurse Specialist, British Columbia
Karen Harkness- Nurse, Clinical Strategist, Ontario (Co-Chair)
Stella Kozuszko- Nurse Practitioner, University Health Network, Ontario

Description:
The COVID -19 pandemic demanded that health care providers rapidly seek ways to provide evidence-based care with significantly restricted in-person access in the outpatient setting. As such, medication optimization for patients with heart failure (HF) was rapidly transformed to virtual modalities in the absence of established guidelines or standardized processes.
The purpose of this workshop is to share the experience of HF nurses and allied health providers across Canada optimizing HF medications using virtual modalities for this patient population. While the opportunity for in-person care has returned, the lessons learned from providing patient care using virtual modalities during COVID-19 pandemic will help inform hybrid models of care that enable clinical best practice for optimizing HF medications and improving patient experience whenever possible.

This workshop aims to raise awareness of the key clinical considerations, enablers and facilitators for providing medication optimization using virtual modalities for patients with heart failure living in the community.

3 speakers with 8 minutes of presentation each followed by discussion and questions with the interdisciplinary panel.

Speaker #1: Virtual medication optimization- Key clinical considerations
Rody Pike
Using a case-based approach, highlight clinical scenarios when virtual medication optimization should be considered or avoided.

Speaker #2: Building an outpatient pharmacist medication optimization care pathway
Lynette Kosar
How do you build, implement and evaluate an outpatient pharmacist-led medication optimization clinical pathway- Where do you get started and what are the critical resources and processes that need to be in place?

Speaker #3: Virtual medication optimization-Where do we go from here?
Wynne Chiu
What was the experience of HF providers delivering virtual medication optimization during COVID-19 pandemic? results from a national survey of tertiary outpatient HF clinics.
How can we take the lessons learned from optimizing HF medication using virtual modalities during COVID-19 pandemic to inform hybrid models of care?